non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive oral myo-inositol (a water soluble six carbon alcoholic sugar) supplement and nutritional recommendation (at the beginning and d
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Age 18-55 years Body mass index in the range of 30-40 Kg / m2 Willingness to cooperate Hepatic steatosis based on Grade 1 and 2 NAFLD disease
Exclusion criteria
Exclusion criteria: Athlete, pregnancy, lactation and menopause in women Infertility treatment, taking oral contraceptive pills Smoking and alcohol use Adherence to a special diet 3 months before the study Use of chemical or herbal medicines for weight loss and use of hepatotoxic drugs such as phenytoin, amoxifine , lithium and insulin sensitizer medications, antibiotics or any kind of supplements that may affect liver enzymes History of weight loss surgery over the last year or rigid weight loss diets three months before the trial Use of NSAIDs or any any multivitamin or supplements for 3 months before or during the study those with cardiovascular disease, hepatic, renal, intestinal, thyroid and parathyroid dysfunction, billiary disease, known autoimmune diseases, PCOs, cancers and conditions use of any antihypertensive drugs and lipid-lowering drugs (statins) and medications related to cardiovascular patients Candidate or history of Liver transplant Intention for pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sirtuin-1 (SIRT-1) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR).;Nuclear factor kappa-B (NF-kB) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR).;Endothelial nitric oxide synthase (eNOS) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR).;Low density lipoprotein receptor (LDLR) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR).;Lectin-type oxidized LDL receptor 1 (LOX-1) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR).;Liver X receptor alpha (LXR-alpha) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR).;ATP Binding Cassette Subfamily A Member 1(ABCA1) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR).;Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) gene expression. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (RT-PCR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: using Seca scale.;Body mass index (BMI). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: According to the formula.;Fatty liver grade. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Ultrasonigraphy.;Total cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic-colorimetric method using spectrophotometer.;Triglyceride. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic-colorimetric method using spectrophotometer.;HDL-C. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic-colorimetric method using spectrophotometer.;LDL-C. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: According to the formula. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNeda Roshanravan
Tabriz University of Medical Sciences
Outcome results
None listed